Nina Skorytchenko is a biotech and business leader with over a decade of experience bridging science and commerce across precision medicine, diagnostics, and digital health. She is the Co-Founder and CEO of Avenna Ltd, a UK-based company developing GlyHealth, a glycomics-based biomarker platform for chronic inflammatory diseases.
Her work focuses on translating complex R&D into scalable clinical and market applications, bringing together biotech innovators, clinicians, and industry partners across the UK, EU, and Spain. Nina has led multiple international collaborations in precision diagnostics, real-world data integration, and multi-omics research, including the ProVision-RA project — a cross-disciplinary initiative aimed at integrating glycomics, proteomics, and clinical data to improve disease-stratification and treatment-response prediction in rheumatoid arthritis.
With a foundation in finance and strategic partnerships (Nomura International, Bloomberg LP, Vestra Wealth), she combines scientific understanding with commercial acumen to accelerate the adoption of data-driven healthcare and AI-enabled biomarker discovery.
Having recently relocated to Valencia, Spain, Nina continues to build bridges between European biotech ecosystems and global markets, promoting collaboration at the intersection of multi-omics, clinical data management, and precision medicine innovation.
Dr Martin Edobor is an NHS GP and Clinical Lead for Digital transformation at North East London ICB. He is the former clinical director for North Newham Primary Care Network and former Chair of the Fabian Society
Angela has been working for the biopharmaceutical Industry for the past 19 years in various roles including clinical development , post marketing research , business operations and real world evidence . She held senior position in Real World Evidence generation at both Sanofi and Bayer and has recently joined EMMEs as head of Real World Evidence. Prior to embarking on a career in the pharmaceutical Industry Angela worked as an Epidemiologist at the LMU Institut of Epidemiology in Munich. Angela holds a Doctorate degree in Environmental Epidemiology as well as a Masters Degrees in Public Health , Nutrition and Business Administration.
Innovation-driven clinician and an enterpreneurial enthusiast based at the Manchester Academy of Health Sciences Centre, Manchester University Hospitals. Recognised as an influential health technology leader with major contributions to innovation in healthcare technology, dialysis and delivery systems.
Passionate about transforming clinical services and patient pathways through enabling technology.
In various leadership roles as Deputy Director of NIHR MedTech Cooperative Devices for Dignity, Vice Chair for EUDIAL, ERA-EDTA, Chair of the Haemodialysis Study group for UK Kidney Research Consortium. Driving safe and value based health care with national organisations as CQC Speciality Advisor, and as Clinical Reference Group Member for NHS England.
Managing a diverse portofolio of translational clinical academic research with a global network of collaborators. A trainer, educator and mentor for health professionals at the University of Manchester. Several publications, patents, authored book chapters and media reports of the work in the field.
Experienced Board level Director and leader within the health and care sector. A values driven leader centred around people, continually striving for innovation and improvements that enhance patient, colleague and customer experience.
My career demonstrates senior positions in the portfolios of organisational development, culture, operational management and delivery, consultancy and quality and improvement transformation roles.
I have purposely gained experience both in the public and private sector, thus operating business and population based leadership and delivery. I am therefore experienced in both commercial and public facing businesses.
Global General Counsel and member of the Amryt Group Executive Leadership Team.
Qualified lawyer in the US (New York), England and Wales and Ireland with experience in Corporate M&A, Tech, Media and Telecoms, Life Sciences and Commercial Contract matters. A proven contract negotiator in the M&A space, with experience in contract drafting and identifying client needs.
Responsible for advising the Amryt Group on M&A, commercial contracts, licensing, data protection, general corporate matters, managing external counsel, global legal budgets and ensuring external legal resources are aligned globally for the Amryt Group.
John was identified and recognised as one of the most influential and innovative General Counsels in the Legal 500 (Legalease) GC Powerlist: Ireland 2022 and GC Powerlist: Ireland Teams 2023. Won Life Sciences Lawyer of the Year at the Irish legal awards and nominated at the Irish Law Awards for Lawyer of the Year; Life Sciences Lawyer of the Year; and In-House Lawyer of the Year 2022.
Experienced strategic leader with extensive experience of operations, business transformation and introducing digital systems. Systems-thinker with focus on delivering cross-sector improvement. Deep knowledge of health and care research regulation and governance.
James has operated at the highest levels of government, including as a Minister at the
Department for Health & Social Care, as Director of the No.10 Policy Unit, and as an advisor to
DHSC Ministers during the COVID-19 crisis. As Minister his responsibilities included
implementing the Life Science Industrial Strategy, delivering a new pricing scheme with the
pharmaceutical industry, chairing the National Genomics Board, and driving the digital
transformation of the NHS. He was also responsible for preparing the health and social care
sectors for Brexit and helping to design the post-Brexit regulatory regime.
James is co-founder and Senior Partner of Newmarket Strategy, a consultancy dedicated to
improving access to health innovation by providing strategic advice and technical support to
the healthcare, life sciences and health tech sectors. He is also a non-executive director at
HDR-UK and the Albion Development VCT plc. In early 2023 James was commissioned by the
Government to carry out an independent review of commercial clinical trials in the UK, which
was published in May.
Helen Boston studied both environmental science and environmental law at the University of Salford, UK, and is now currently studying for an MBA in Sustainability at the Sustainability Management School Switzerland (SUMAS). Since leaving university, Helen has worked in product stewardship, regulatory affairs and sustainability roles for several large chemical companies. Helen joined RAHN in November 2021 as Head of Regulatory Affairs EnergyCuring.
